BOCA RATON, Fla., April 10 /PRNewswire/ -- Breckenridge announced today that it has entered into an agreement with Orit Laboratories to market 2 separate generic ANDA products. The first project is currently filed and pending FDA approval. The companies plan to file an ANDA with the FDA for the second product in the 3rd Quarter of 2008. Upon approval by the FDA, both products will be supplied by Orit Laboratories, and will be marketed and distributed by Breckenridge Pharmaceutical, Inc., on an exclusive basis in the USA.
Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand(TM) and Generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, including multiple ANDA's, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. www.bpirx.com
About Orit Laboratories:
Orit Laboratories specializes in the development of specialty generic pharmaceutical prescription products. The company focuses on the development of solid, liquid, soft gelatin capsule, modified release, and orally disintegrating dosage formulations using proprietary Drug Delivery Platforms. Orit Laboratories operates an FDA registered cGMP facility in West Caldwell, New Jersey that is approximately 10,000 sq. ft. The company is capable of pilot scale production, and their analytical laboratory operates under cGMP & cGLP. Orit has capabilities of Regulatory filing with the US Food and Drug Administration (FDA).
SOURCE Breckenridge Pharmaceutical